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Hyperthermia means overheating of the living object completely or partly. Hyperthermia, the procedure of raising the temperature
of a part of or the whole body above normal for a defined period of time, is applied alone or as an adjunctive with various
established cancer treatment modalities such as radiotherapy and chemotherapy. However, hyperthermia is not generally accepted
as conventional therapy. The problem is its controversial performance. The controversy is originated from the complications of the
deepheating and the focusing of the heat effect.The idea of oncothermia solves the selective deep action onnearly cellular resolution.
We would like to demonstrate the force and perspectives of oncothermia, as a highly specialized hyperthermia in clinical oncology.
Our aim is to prove the ability of oncothermia to be a candidate to become a widely accepted modality of the standard cancer care.
We would like to show the proofs and the challenges of the hyperthermia and oncothermia applications to provide the presently
available data and summarize the knowledge in the topic. Like many early stage therapies, oncothermia lacks adequate treatment
experience and long-range, comprehensive statistics that can help us optimize its use for all indications.
1. Introduction
In oncology, the term “hyperthermia” refers to the treatment
of malignant diseases by administering heat in various
ways. Hyperthermia is usually applied as an adjunct to an
already established treatment modality (radiotherapy and
chemotherapy), where tumor temperatures in the range of
40–46∘C are aspired. Interstitial hyperthermia, hyperther-
mic chemoperfusion, and whole-body hyperthermia are still
under clinical investigation, and a few positive comparative
trials have already been completed. In parallel to clinical
research, several aspects of heat action have been examined
in numerous preclinical studies.
The traditional hyperthermia is controlled the only single
thermodynamic intensive parameter, with the temperature.
Oncothermia, which is a “spin-off” form of the hyperthermia,
is based on the paradigm of the energy-dose control, replac-
ing the single temperature concept [1]. With this approach,
oncothermia returned to the gold standards of the dose
concepts inmedicine; instead of the parameter, which cannot
be regarded as dose (the temperature does not depend on the
volume or mass), oncothermia uses the energy (kJ/kg [=Gy])
like the radiation oncology uses the same (Gy) to characterize
the dosing of the treatment.
This paper deals with discussions concerning the direct
and indirect cytotoxic effect of heat and energy; heat-and
energy-induced alterations of the tumor microenvironment;
synergism of heat in conjunction with radiation and drugs;
the presumed cellular effects of hyperthermia and oncother-
mia including the expression of heat-shock proteins (HSPs),
induction and regulation of apoptosis, signal transduction,
and modulation of drug resistance by hyperthermia or
oncothermia.
2. Biophysical and Metabolic Differences
between Healthy and Cancerous Cells
The clue to find the mechanisms, which could create the
requested optimization, selection and control of the energy
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intake based on the clear biophysical differences between
healthy and cancerous cells, finding the biophysical property
to focus the energy on the desired cellular membranes. The
main difference could be found in the metabolic processes
of malignant cells and their healthy counterparts. In con-
sequence of the physical differences, the malignant cell are
distinguishable by their biophysical parameters. The electric
properties of the cancerous cells differ from normal, and the
main differences are.
(i) The efficacy of the ATP production in cancerous cell
is low. The large ATP demand for the proliferative
energy consumption allows less ATP for active mem-
brane stabilization by K+ and Na+ transport; so the
membrane potentiating weakens.
(ii) The cellular membrane of cancerous cells is anyway
electrochemically also different from the normal, as
well as its charge distribution also deviates.
(iii) Themembrane of the cancerous cell differs in its lipid
and sterol content form their healthy counterpart.
(iv) The membrane permeability is changed by the previ-
ous differences. In consequences of these, the efflux
of the K+, Mg2+, and Ca2+ ions, while the efflux
of Na+ decreases together with the water transport
from the cell. Consequently the cell swallows, its
membrane potential decreases further. (The efflux
of K+ regulates the pH of the cell and takes the
protons out form the cytosol.) The concentration of
Na+ increases in the cytosol, and parallel of this,
the negative ion-concentration also grows on the
glycocalix shell, decreasing the membrane potential
and the tumor will be negatively polarized in average.
This fact was well used for direct current treatment
(electrochemical cancer therapy (ECT)) by Norden-
strom and others.
(v) The conductivity and the dielectric constant of the
tumor tissue will be higher than normal.
The healthy cells work collectively, and their energy-
consumption as well as their life-cycles and the availability
of resources are controlled on collective way by the various
form of the self-organizing.The healthy cells are organized in
this way, and their standard cycles, reactions, and structures
are complexly regulated in both internal and external areas.
The malignant cells behave in completely different way.
This process is the “ancient” chemical reaction, which was
characteristic at the beginning of the evolution of the life,
when the oxygen, the general electron acceptor, was available
only in a small amount in the atmosphere. It is the fermenta-
tive way to utilize the energy of glucose converts it into lactic
acid (CH
3
CHOHCOOH), producing 2 ATPs in one cycle,
while the healthy cycle (Krebs cycle) produces 36 ATPs [2].
The enormously large demand of malignant cells for
nutrients, not only the ionic density in the surrounding,
makes the malignant cells distinguishable, but their structure
is also very different. Their demand for the huge energy
production pushes them for the permanent competition
for the sufficient amount of nutrition. The cells became
independent competitors instead of the normal cooperation,
and the harmony had been replaced by autonomy. The
intercellular contacts in healthy network are broken in cancer,
the order of the tissue had been lost, and the “social signal”
between the cells vanished. The malignant cells become
disordered, nonconnected, and isolated. The malignancy has
definitely different structure that its healthy counterpart, and
its dielectric constant and optical refractive index deviates
from normal.The lost intercellular contacts block the natural
control over the structural changes, and the disordered
structure changes the optical properties also [2].
3. Hyperthermia
Hyperthermia is the process of raising the body temperature,
either locally or globally, formedicinal purposes. Historically,
hyperthermia has been recognized for its curative power
in treating tumors [3, 4]. The first application of hyper-
thermia for regional cancer control dates to 1898 when the
Swedish gynecologist Westermark [5] treated cervical cancer
by running hot water through an intracavitary spiral tube.
He noted excellent clinical response in the seven patients
treated. More recent clinical studies have shown that the
success of a hyperthermia cancer treatment is related to the
minimum temperature rise occurring in the tumour tissue
[6, 7]. Unfortunately, prolonged exposure of normal, healthy
tissue to elevated temperatures has a detrimental effect [8].
3.1. The Basic Concept. To reach temperatures clearly above
the systemic temperature of 37.5∘C in a defined target volume
is a technical challenge. The effectiveness of hyperthermia
treatment is related to the temperature achieved during the
treatment, as well as the length of treatment and cell and
tissue characteristics. To ensure that the desired tempera-
ture is reached, but not exceeded, the temperature of the
tumour and surrounding tissues is monitored throughout
the hyperthermia procedure. Another important challenge
was to minimize damage to healthy tissue and other adverse
effects, and physicians carefully monitor the temperature of
the affected area.The goal is to keep local temperatures under
44∘C to avoid damage to surrounding tissues, and the whole
body temperatures under 42∘C, which is the upper limit
compatible with life.
Most clinical hyperthermia systems operate by causing a
target volume of tissue to be exposed to electromagnetic or
ultrasound radiation. A structure is needed that is capable
of transferring energy into biological tissue and getting
the best approximation of the area to be treated by 3D
distribution of SARs. The majority of the hyperthermia
treatments are applied using external devices (applicators),
employing energy transfer to the tissue [9, 10]. For a heating
system to be effective, it must be able to produce final
time and temperature histories that include a set of tumor
temperatures that can be maintained for long enough times
to result in clinically effective thermal doses without also
producing unacceptable normal tissue temperatures [11].
A great deal of current research focuses on precisely
positioning heat-delivery devices (catheters, microwave and
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ultrasound applicators, etc.) using ultrasound or magnetic
resonance imaging, as well as developing new types of
nanoparticles that make them particularly efficient absorbers
while offering little or no concerns about toxicity to other
tissues. Applicators are positioned around or near the appro-
priate region, and energy is focused on the tumor to raise its
temperature. To describe the different applicators and hyper-
thermia methods is not our aim in this paper; however, the
summary of the effects of regional especially the locoregional
hyperthermia on cell and tissue level is in the next chapters.
Regional hyperthermia heats a larger part of the body, such
as an entire organ. Usually, the goal is to weaken cancer cells
so that they are more likely to be killed by radiation and
chemotherapeutic medications.
3.2. Mechanisms of Hyperthermia. The cellular effect of
hyperthermia is more complicated. Briefly, hyperthermia
may kill or weaken tumor cells, and is controlled to limit
effects on healthy cells. Tumor cells, with a disorganized
and compact vascular structure, have difficulty dissipating
heat. Hyperthermia may therefore cause cancerous cells to
undergo apoptosis in direct response to applied heat, while
healthy tissues can more easily maintain a normal tempera-
ture. Even if the cancerous cells do not die outright, they may
become more susceptible to ionizing radiation therapy or to
certain chemotherapy drugs, which may allow such therapy
to be given in smaller doses. Intense heating will cause
denaturation and coagulation of cellular proteins, rapidly
killing cells within the targeted tissue. A mild heat treatment
combined with other stresses (excitation of the appropriate
signal pathways) can cause cell death by apoptosis. There are
many biochemical consequences to the heat shock response
within the cell, including slowed cell division and increased
sensitivity to ionizing radiation therapy. Hyperthermia can
kill cells directly, increasing blood flow to the warmed area,
perhaps doubling perfusion in tumors, while increasing
perfusion in normal tissue by ten times or even more [12].
This enhances the delivery of medications. Hyperthermia
also increases oxygen delivery to the area, which may make
radiation more likely to damage and kill cells, as well as
preventing cells from repairing the damage induced during
the radiation session.
While it is acknowledged that at the tissue, organ,
and whole body level there are numerous effects that can
contribute to the clinical uses of hyperthermia, this review
focuses mainly on effects at the cellular level. The goal of
hyperthermia research is to find the molecular mechanisms
by which heat kills tumour cells or any cells and the
mechanisms by which hyperthermia radiosensitizes cells to
radiation or chemotherapeutic agents. A major problem is
that hyperthermia causes a large number of macromolecular
changes and affects functions in all cellular compartments at
temperatures above 43∘C.
The potential importance of the hyperthermia for cancer
treatment has been highlighted byCoffey et al. [13, 14]. Specif-
ically, the review addresses four topics: (1) hyperthermia
induced cell killing, (2) vascular, (3) cellular and intracellular
mechanisms of thermal effects in the hyperthermia temper-
ature range, and (4) effects on proteins that contribute to
resistance to other stresses, for example, DNA damage.
3.3. Vascular Changes of Thermal Effects in the Hyperthermia.
Mild heat temperatures cause an increase in blood flow.
At the same time, there is a corresponding increase in the
oxyhaemoglobin saturation of the individual red blood cells
within tumour microvessels. These changes will lead to an
overall increase in oxygen availability and improve tumour
oxygenation status [15, 16]. At higher temperatures one may
see a very transient increase in blood flow during the heating
period, but vascular damage soon begins to occur and this
will rapidly lead to a decrease in tumour blood flow [17–19].
With higher heat temperatures, there is also a corresponding
decrease in oxyhaemoglobin saturation, and these changes
will result in a decrease in overall oxygen availability.This lack
of oxygen will also give rise to a decrease in tumour pH and
ultimately lead to ischemia and cell death [17]. The degree of
vascular shutdown at the higher temperatures appears to be
dependent on the time and temperature of heating and the
tumour type. Normal tissues typically show a very different
vascular response to heat, with flow essentially increasing as
the temperature increases, even at temperatures that produce
substantial vascular occlusion in tumours [20, 21].
3.4. Thermal Cell Killing and Other Cellular Effects of Hyper-
thermia. In the hyperthermia, the main effects at the cellular
level that are of relevance to cancer therapy are cell killing.
It has been long recognized that hyperthermia in the 40–
47∘C temperature range kills cells in a reproducible time
and temperature dependent manner. In the hyperthermic
region there are three particularly significant and important
cellular responses for thermal therapy: cytotoxicity, radiosen-
sitization, and thermotolerance [22, 23]. Survival curves for
temperatures in the 43–47∘C range typically show a shoulder
with an exponential reduction in clonogenic survival as a
function of time at a given temperature [14]. The “shoulder”
of the survival curve reflects a two-step process of cell
killing. This is marked by a linear growth arrest in the
beginning of heat exposure (reflecting a reversible, nonlethal
heat damage), that is followed by exponential cell death. One
fundamental observation is that the capability to induce cell
death in vitro at lower temperatures <42–43∘C is markedly
lower than above 43∘C [14].
The changes induced by hyperthermia at the cellular level
must be due to temperature-induced alterations in molecular
pathways, which usually involve inhibition of DNA, RNA,
and protein synthesis [23]. However, while protein synthesis
is inhibited during heating at higher temperatures, at milder
temperatures and after return to normal growth temperature
the induction of heat shock proteins occurs [24], which is an
inducing event and closely associated with the induction of
thermotolerance.Thus, heat shock can lead to both inactivat-
ing and activating responses. A fundamental question is the
identity of themolecular events leading to the cellular sensing
of altered temperature with subsequent alterations in cellular
function. The principal conclusion from these studies is that
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for hyperthermia, thermal dose is a combination of time and
temperature.
The intensity of cell death in hyperthermia is showed
cell cycle dependence. In general, high heat sensitivity
can be observed during the S and M phases. Microscopic
examinations of M-phase cells subjected to hyperthermia
show damage of their mitotic apparatus leading to inefficient
mitosis and consecutive polyploidy. S-phase cells are also
sensitive to hyperthermia, where chromosomal damage is
observed. Both S- andM-phase cells undergo a “slowmode of
cell death” after hyperthermia, whereas those exposed to heat
during G1-phase are relatively heat resistant and do not show
anymicroscopic damage. Cells during G1-phase may follow a
“rapidmode of death” immediately after hyperthermia.These
variations existing between the different cell cycle phases
indicate the possible diversity of molecular mechanisms of
cell death following hyperthermia [24–26].
The thermal reactions promote numerous other effects
than simple cell-killing. The most important for this com-
plementary therapy are those effects that alter the resistance
of cells to radiation and/or chemotherapeutic agents. The
challenge is to determine which molecular changes are
critical for the relevant endpoint such as tumour cell killing
and sensitization to chemo- and radiation therapy [3, 27].
To answer the question, there is an unfolding story of
tumour pH and its consequences have become clearer over
the last two decades [2]. Using new intracellular methods
the intra- and/or extracellular pH is measurable in tissues.
Under many conditions it has now been confirmed that
the intracellular pH in tumour cells is neutral to alkaline
as long as tumours are not oxygen and energy deprived
[28]. Tumour cells have mechanisms for exporting pro-
tons into the extracellular space. It means that a strong
pH gradient exists across the cell membrane in tumours
(pHi > pHe). Interestingly, this gradient is the reverse of
that found in normal tissues where pHi is lower than pHe
[9, 29, 30]. Under anaerobic condition cancer cells intensively
split glucose to lactic acid, and other relevant pathogenetic
mechanisms yielding an intensified tissue acidosis are based
on substantial ATP hydrolysis, glutaminolysis, ketogenesis,
and CO
2
/carbonic acid production. Acidosis can sensitise
tumour tissue to single heat treatments and to fractionated
hyperthermia. Summarising the relevant data, it can be
stated that tumour temperatures >42.5∘C, and appropriate
heating can reduce both intracellular and extracellular pH,
which may further sensitise tumour cells to hyperthermia in
the sense of a positive feedback mechanism [28]. Relevant
pathogenetic mechanisms leading to an intensified acidosis
upon heat treatment (which is reversible after hyperthermia)
are
(1) an increased glycolytic rate with accumulation of
lactic acid,
(2) an intensified ATP-hydrolysis,
(3) an increased ketogenesis with accumulation of ace-
toacetic acid and 𝛽-hydroxybutyric acid,
(4) an increase in CO
2
partial pressures,
(5) changes in chemical equilibria of the intra- and
extracellular buffer systems (DpH/DT = −0.016 pH
units/C),
(6) an inhibition of the Na+/H+ antiporter in the cell
membrane [3, 31].
The ATP decline observed upon heat treatment is mostly due
to
(1) an increased ATP turnover rate (i.e., intensified ATP
hydrolysis), and as a result of an increased ATP
degradation, an accumulation of purine catabolites
has to be expected together with a formation of H+
ions and reactive oxygen species at several stages
during degradation to the final product uric acid,
(2) a poorer ATP yield as a consequence of a shift from
oxidative glucose breakdown to glycolysis [28].
The significance of the baseline pH
𝑒
and pH
𝑖
values and
changes occurring during hyperthermia in clinical studies
still remains unclear, since—in contrast to in vitro and in
vivo data derived from experimental tumours treated with
hyperthermia alone—the results are equivocal so far. Further
clarification of these effects is urgently needed.
Thermal sensitivity has been shown to greatly depend on
the efficacy of tumour blood flow and parameters defining
the metabolic microenvironment such as hypoxia, acido-
sis, substrate deprivation, accumulation of metabolic waste
products, and energy depletion. If recent experimental data
are critically evaluated, there is some evidence that besides
microcirculatory function, intracellular pH and the bioener-
getic status may be decisive factors ultimately modulating the
thermosensitivity of cancer cells.
Israe¨l and Schwartz [2] in 2011 summarized the
metabolism of cancer cells. Briefly, in tumour cells the
glycolysis is elevated, but a pyruvate kinase (PK) “bottleneck”
interrupts phosphoenol pyruvate (PEP) to pyruvate
conversion.Thus, alanine following muscle proteolysis trans-
aminates to pyruvate, feeding lactate dehydrogenase,
converting pyruvate to lactate (Warburg effect) and NAD+
required for glycolysis. Cytosolic malate dehydrogenase also
provides NAD+ (in OAA to MAL direction). Malate moves
through the shuttle giving back OAA in the mitochondria.
Below the PK-bottleneck, pyruvate dehydrogenase (PDH)
is phosphorylated (second bottleneck). However, citrate
condensation increases; acetyl-CoA will thus come from
fatty acids b-oxydation and lipolysis, while OAA sources are
via PEP carboxy kinase and malate dehydrogenase (pyruvate
carboxylase is inactive). Citrate quits the mitochondria,
(note interrupted Krebs cycle). In the cytosol, ATP citrate
lyase cleaves citrate into acetyl CoA and OAA. Acetyl
CoA will make fatty acids triglycerides. Above all, OAA
pushes transaminases in a direction usually associated to
gluconeogenesis! This consumes protein stores, providing
alanine (ALA); like glutamine, it is essential for tumors.
The transaminases output is aspartate (ASP) it joins with
ASP from the shuttle and feeds ASP transcarbamylase,
starting pyrimidine synthesis. ASP in not processed by
argininosuccinate synthetase, which is blocked, interrupting
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the urea cycle. Arginine gives ornithine via arginase, and
ornithine is decarboxylated into putrescine by ornithine
decarboxylase. Putrescine and SAM form polyamines
(spermine spermidine) via SAM decarboxylase. The other
product 5-methylthioadenosine provides adenine. Arginine
deprivation should affect tumors. The SAM destruction
impairs methylations, particularly of PP2A, removing the
“signaling kinase brake,” PP2A also fails to dephosphorylate
PK and PDH, forming the “bottlenecks.” (Black arrows =
interrupted pathways.).
Israe¨l and Schwartz [2] suggested some new cancer treat-
ments based on the previously describedmetabolic advantage
of tumour cells.
(1) Inhibit alanine transaminase, glutaminase, ornithine
decarboxylase, and arginase and decrease alanine,
glutamine, arginine, and supplies.
(2) Open PK and PDH bottlenecks (enzyme kinase inhi-
bition and PP2A phosphatase activation by methyla-
tion helpers).
(3) Close citrate synthase, ATP citrate lyase, and increase
the NADHmitochondrial potential.
(4) Decrease GH/IGF and “tyrosine kinase receptor”
signals.
(5) Cancel epigenetic changes using HDAC inhibitors
and then HAT inhibition
(6) Boost immune NK protection.
So important is the steps 1–4 showing strong ATP depen-
dence. The hyperthermia treatment as we described before
reduces the intracellular ATP concentration. The major con-
sequence of the low ATP is the inhibition the ATP dependent
enzyme activity.
3.5. Effects on Heat Shock Proteins and the Consequent
Immunomodulation. Protein damage is the main molecular
event underlying the biological effects of hyperthermia in the
clinically relevant temperature range (39–45∘C). The activa-
tion energies for protein denaturation and heat-induced cell
death are within the same range [32]. Despite the fact that
it is known that protein damage plays a central role in the
biological effects of hyperthermia, little is known about what
finally kills the cells [33]. Temperature elevations transiently
upregulate heat shock genes that encode a class of heat shock
proteins (HSPs). The mechanism responsible for the heat
shock response is an autoregulatory loop; HSPs normally
keep the responsible transcription factor (HSF-1) inactive
but upon heating HSP bind with higher affinity to unfolded
proteins, triggering the release of HSF-1 from HSP which
initiates HSP gene transcription. Once the protein dam-
age/aggregation is restored after the heat shock by the HSP,
substrate-free HSP themselves seem involved in attenuating
the response by rebinding HSF-1 [34]. As a result, HSP levels
transiently rise after heating but also gradually decline again
upon prolonged stress free periods. The upregulation of HSP
is closely associated with a transient resistant state of cells
towards a subsequent second heat shock. It is thought that
the elevated HSP levels, by their chaperone activity, protect
cells against protein damage induced by the 2nd heating.
HSPs were originally described with respect to their
roles as chaperones induced by temperature shock as well as
various other types of stress [12]. HSP are usually divided
into small HSP (molecular mass less than 40 kDa) and the
HSP 60, HSP 70, HSP 90, and HSP 100 proteins families.
Today, at least HSP 27 and HSP 70 are supposed to represent
“general survival proteins” that are able to defend cells against
a variety of potentially lethal (proapoptotic) stimuli [12].
In hyperthermia, HSPs are thought to be involved in the
protection of cells against heat damage. Intracellular HSP
synthesis increases when cultured cells are exposed to mod-
erate heat application. At higher temperatures, inhibition of
HSP synthesis occurs above a distinct threshold temperature.
In general, the temperature, respectively, thermal dose, at
which HSP synthesis is inhibited in a given experimental
system varies between different cell types, but the respective
threshold can be loweredwhen further (proapoptotic) stimuli
are added. As lack of HSP synthesis is associated with
exponential cell death, and it is generally accepted that HSPs
prevent cells from lethal thermal damage [12, 35–37].
Recently, an additional role has been ascribed to HSPs
which should be importance in hyperthermia as activators
of the immune system. The importance of the HSP fam-
ily, including HSP70 and HSP90 in immune reactions has
been demonstrated, and several researchers have reported
that heat-treated tumor cells can play a vaccine-like role
and elicit antitumor immunity [12, 35–37]. HSP have been
found to play important roles in eliciting potent anticancer
immune responses mediated by T-cells, antigen-presenting
cells (APCs), and natural-killer (NK) cells. In order to explain
the paradoxical situation of how highly conserved HSP
mediate cancer immunity, Srivastava et al. [38] proposed the
following four paradigms:
(a) due to short nonconserved immunogenic regions,
(b) because a tissue specific expression pattern HSP can
act as classical foreign antigens,
(c) HSP could mimic classical T-cell epitopes,
(d) act as carrier molecules for immunogenic peptides.
Presently, experimental evidence exists for possibilities (a)
and (c). Tumour-derived HSP (HSP 70, Hsc70) and gp96
have been shown to chaperone immunogenic peptides to
MHC molecules that elicit T-cell responses against primary
tumours and metastases. Antigen-presenting cells have been
found to be key for mediating this specific immune response.
The membrane-bound HSP 70 provides a target recognition
structure for transiently plastic adherent NK cells. A corre-
lation of the cytolytic activity of NK cells with the amount
of plasma membrane-bound HSP 70 has been determined.
Although an HSP 70-NK cell interaction could be demon-
strated in binding studies (unpublished data), themechanism
of how NK cells lyse Hsp70 positive tumour target cells
remains to be elucidated. HSP 70 expressing tumour cells
are more sensitive to lysis mediated by IL-2 stimulated,
transiently plastic adherent NK cells, as compared to HSP
70 membrane negative tumour cell. Selectively transiently
6 Evidence-Based Complementary and Alternative Medicine
plastic adherent NK cells, but not T-cells, exhibit an increased
cytolytic activity against Hsp70 membrane positive tumour
target cells [12, 35–37].
In summary, the data provide evidence that membrane-
bound HSP 70 or the extracellular exposed HSP 70 peptide
TKD might provide a tumour-selective target recognition
structure for CD94 positive NK cells. The elucidation of
potential coreceptors or partner molecules of CD94 that
mediate triggering signals following contact with HSP 70
protein or HSP 70 peptides is currently under investigation.
4. Problem with the Hyperthermia
The requested job is to kill themalignant cells, for what a defi-
nite energy dose is necessary [39].Thehistorical energy-dose-
like control (temperature multiplied by its application time)
is physically incorrect and operates with an overall energy
average in the area, instead of a directed and well-measurable
energy dose (measured in kJ). The high energy application
could cause controversies the high temperature burns the
malignant cells but because it is missing selectivity and it
damages the healthy cells and starts unwanted physiological
reactions as well as enlarged dissemination possibility. These
conditions make the hyperthermia effect not controlled,
irrespective that the temperature could be kept on a certain
level in the tumor or not. In reality the selectivitywhichwould
be necessary for the actions ismissing, and the heating attacks
all the cells in the target and also unselectively provokes the
psychological control and regulation.The original idea of the
hyperthermia was the “fire by fire” concept; set a controlled
contrafire depleting the possible firesupply, blocking the
coming large bush-fire endangering a house. The heated
tumor is forced to higher metabolism; high metabolic rate of
the cancer lesion is gained by elevated temperature. However,
when the surrounding is intact, it delivers the same amount
of nutrients than before and does not deliver more glucose
for the forced metabolism. The tumor very quickly deflates
from nutrients, empties all its energies, suffers, and burns
away. However, by the large heating energy heats up the
healthy surrounding us well, the blood flowwill be enhanced,
the nutrients supply will be higher, we make opposite than
our aim was to do. The situation became even worst by
continuing the high-energy heating: the high bloodflowhelps
the dissemination and could gain the metastases. With this
we can definitely worsen the survival and the quality of life of
the patient. The blood flow is an important thermodynamic
modification factor, which makes the dominant addition to
the temperature development in the tumor. According to the
fits of measurements, actually the blood flow for tumor and
the healthy tissues are both definitely temperature dependent,
and in general there is a threshold when the blood flow of the
tumor became lower than the blood flow of the healthy sur-
roundings. Below this threshold the efficacy of radiotherapy
(which is propositional with the oxygenation of the tissue)
and the chemotherapy, which is proportional with the drug-
concentration in the tissue) is growing by the increasing of the
temperature, because both of these properties are delivered
by the increasing blood-flow. However, the complementary
therapies over the threshold are suppressed by the decreasing
of the blood-flow in the tumor.
5. Change of Paradigm: The Oncothermia
Oncothermia technology heats nonequally; concentrating
the absorbed energy to the intercellular electrolytes [40].
This method creates inhomogeneous heating, microscopic
temperature differences far from thermal equilibrium. The
definitely large temperature gradient between the intra-
and extracellular liquids changes the membrane processes
and ignites signal pathways for natural programmed cell-
death, avoiding the toxic effects of the simple necrosis. The
synergy of electric field with the thermal effects potently and
selectively makes the job [41].
5.1. How the Oncothermia Works, Generally. Advantage of
oncothermia, that while the classical artificially focused
hyperthermia has to heat up in case of the multiple lesions
overlapping all the volume, which contains these lesions;
contrary, oncothermia automatically focuses on the lesions
in their multiple places, without treating the healthy tissue
between. Oncothermia has a simple technical setup. The
modulated radiofrequency current (RF) flows through the
lesion. The RF current which flows through the cancerous
lesion automatically focused by its lower impedance will
flow mainly in the extracellular electrolyte, because the cells
are electronically isolated by their membrane by more than
one-million V/m field strength. The membrane disruption
is one of the targeted aims, and many research groups are
dealing with the electric field action on the cellular divisions.
The main advantage of the electric field application is the
missing control of the organism, physiology control over this
effect; no physiology feedback is directly limiting the electric
field and only its consequences could be regulated. The
process made by oncothermia has its main energy delivery
into the extracellular liquid, heating it up, and creating
a little (1/1000∘C) difference between the inner and outer
temperature of the cell. This looks only a small difference,
but regarding of the very tiny membrane layer (5 nm),
the small difference in standard conditions is pretty high:
∼200,000∘C/m! This starts a prompt heat flow from outside
to the cell through the membrane and permanently acts till
the temperature difference exists. Despite of the quick heat-
flow through this tiny membrane, the heat current is long-
lasting, till the full cellular interior is not heated up to the
same temperature than outside [42–44].
Oncothermia does not require high temperature for the
treatment, the energy used for distortion of the selected
malignant cells is that of thermodynamic effects (heat-
flows are applied instead of the general average isotherms).
Oncothermia is based on the modulated electric field effect,
which works in synergy of the classical temperature-based
hyperthermia concept. In preclinical conditions (in vivo and
in vitro) many measurements were done in animals and
there are many interested users who tried up till now the
temperature development by themethod, which is a complex,
invasive measurement approach. A well-controlled clinical
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temperature measurement by the CT-guided fluoroptic sen-
sor showed the temperature increase facility of oncothermia
also [44].
However, the main advantage of oncothermia is that
the nonequilibrium heating creates a heat-flow through the
membrane into the cytosol, which is active till the equilibrium
is reached. This gains the efficacy and the reliability of
the treatment. The membrane effect by electric field was
expected having a thermal limit. It was questioned, and
later it was rigorously shown that the effect of oncothermia
is not limited in this issue. To enhance the selection for
membrane distortion, and enhance the collective (apoptotic)
control on the cell-death, a special modulation is built in the
oncothermia process [45].
The not so high radiofrequency (13.56MHz) is absorbed
in all the electrolytes, but the main energy absorption is in
the membrane and the extracellular electrolyte. This creates
an extreme SAR between the cells, which makes temperature
gradient through the membrane. The treated tissue will be
inhomogenicly heated, and heat flows from extracellular to
cytosol through the membrane, accompanying with definite
other thermodynamical and chemical changes.These definite
thermal currents will be continued till the extra- and intra-
cellular temperature reaches equilibrium; so the intracellular
electrolyte had been heated up to the equal level.
5.2. Oncothermia Is Microscopic Heating of Nanoscopic Tar-
gets. The general idea of microscopic heating is simple; the
heating energy is not liberated in a sudden single step, but
regulated and multiple small, microscopic energy liberation
makes the same job. In our case the forwarded energy
targets the most influential areas selectively. Instead of the
high, general energy pumping into the lesion, the energy
is liberated at the membranes of the malignant cells, in a
nanometer range. Anyway, the microscopic effect, instead of
the large energy liberation, is one of themost update thinking
in energy source developments. In the modern technologies,
the relatively low efficacy combusting engines are intended
to replace by the fuel-cell energy sources and electric motors,
which are based on the membrane regulated microscopic
reactions of gases. In our case the microenergy liberation at
the nanoscopic cellularmembrane hits themost sensitive part
of the tumor cells.
The efficacy of the energy depletion intended to pump
into the tumor is limited by the energy loss outside of the
malignant target. The main factors of the useless energy
absorptions are
(i) the absorbed energy by the tissues transfers the effect
to the deep-seated tumor;
(ii) the heat exchange by the blood flow;
(iii) the heat exchange by the heat conduction from the
tumor to the surroundings;
(iv) these heat sinks are modifying the overall perfor-
mance of the treatment and make uncontrolled the
full heating process for themalignancy.The real effect
which used for the intended treatment is to be less
than the losses, and the efficacy is usually less than
25%, which is very low. The problem of this is not
only that the large part of energy is wasted, but also
the useless energy part could be dangerous by over-
heating the healthy tissues as well as increasing the
metabolic rate and also making physiology answer on
this effect which tries to break the homeostasis. The
massively heated tumor volume intensifies the control
of physiology and weakens the expected effect.
The adequate corrective actions for these challenges would
be the more precise targeting, decreasing the losses in
the surrounding and avoid the physiological corrections to
suppress the desired effect. Construction the solution some
new effects have been used increasing the efficacy.
(i) Apply the electric field as carrier of the energy, and
that field cannot be compensated by homeostatic
control.
(ii) Apply a correct microscopic targeting, using the
energy absorption cell-by-cell efficiently.
(iii) Apply such mechanisms, which initializes natural
effects kill the malignant cells.
(iv) Apply mechanism, which carries information for
disseminated cells to be blocked.
According to the calculations a relatively small amount of
energy can heat up the average-sized tumors to the appro-
priate temperature, if it targets the tumor accurately enough.
The relatively low bioimpedance of malignant lesions makes
possible the automatic focusing; the applied RF-current will
choose the “easiest” way to flow, automatically loading the
tumor with highest current density [46].
The approach using electric impedance for quality assur-
ance is partly comparable with the ion concentration concept
of ionizing radiation characterization: the old unit measured
the ion pair production, 1 R (roentgen) = 2.58 ∗ 10−4 C/kg.
Note, interestingly, that an electric field application without
an increase in temperature (using less than 5W power)
has also been found effective against cancer, by using gal-
vanic (DC) current applications, producing ion-pair effects
in extracellular electrolyte. This electric tumor treatment
measures and controls the tissue resistance and the quality
parameter is the applied charge load (in Coulombs, C),
with results reported in several peer-reviewed journals and
conferences organized on the subject. Yet few studies discuss
the biological mechanisms involved in electromagnetic field
induced hyperthermia. However, the effect of electric field
remains to be a hot topic in science [40].
Oncothermia works with much less forwarded energy,
by focusing energy directly on the malignant tissue using
its impedance selectivity even by cellular resolution. This
effect is based on the low impedance of the tumor, due to its
metabolism, which is higher than that of its healthy counter-
part’s. This special focusing in fact makes the treatment safer
and really nontoxic. The high and fermentative glucose→
2ATP process [3, 47] produces higher ionic concentration in
the more active cellular environments and different physio-
logical conditions and allows even spatial resolution by this
effect. The real focusing could be measured by RF-current
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Figure 1: The cell-destruction ability of oncothermia is three times higher than of conventional hyperthermia at the same 42∘C temperature
(single shot treatment, 30min). Pumping the same energy as for temperature 42∘C, but cooling the lesion by outside water-bolus (to 38∘C
temperature), the efficacy of the cell-destruction remained much higher in oncothermia than in hyperthermia at 42∘C temperature.
density image, which spectacularly shows the focusing of the
current in the tumor. The focusing effect in this meaning is
very similar to the PET picture, which shows the enhanced
metabolic activity of the tumor.
Model of oncothermia method producing higher effi-
cacy could be demonstrated with a simple parallelism with
the solutions of modern energy sources. The conventional
engines in vehicles use the energy of explosion of different
chemicals (e.g., petrol, diesel, and kerosene).The explosion by
a spark or heating over their activation energy liberates large
energy in a short time, and only a small fraction of this could
be applied beneficially, while most of the energy is radiated,
conducted, or lost in various other ways. One of the largest
loss is the heat exchange by the high temperature, which
somehow has to be used again (e.g., intercooler and turbo).
Themost modern solution, however, is the set of microscopic
explosions, promoting the chemical reactions individually
by a membrane control (i.e., fuel cell solution) and using
the energy step-by-step as a sum of the microreactions. This
model is anyway learned from the living organisms, when
the energy is liberated gradually in a “ladder” of multistep
processes, and also moderated by surface reactions.
In this case, the lost energy is minimal; the efficacy
of the energy utilization and its control is maximal. The
energy is concentrated in this case directly to the chemical
reactions and does not involve the previously listed losses.
The energy liberated by the microreactions are used for the
desired job in full, while the explosion-like, huge energy-
supply in short time cannot be optimally used, because the
intensity of the immediate offer for the available energy is
too much for prompt use. This causes a large demand of
waste and a low efficacy of the desired effect. The problem
of the heating however shows a false, specious effect of
applications in biology.When the liberated energy is not used
as active biochemical or biophysical driving-force than the
waste appears as a simple growth of the temperature in the
target. This deceptive illusion looks as higher efficacy. This
process is of course a better heating, wasting the energy and
not used for the actually necessary processes, distributing the
excess energy in the neighborhood, and gaining the average
energy of all the particles in the target.
This is a typical loose of aims by illusions: the temperature
makes only conditions that are implements and not the aim.
The question “Tool or goal?” became relevant to study the
temperature alone. By a simple example of mixing the tool
and the goal in our everyday life, the graduation is a tool
for our professional life, however, when somebody makes
regards the certificate of studies as a goal, its application,
the aim of the study looses. Mixing the tool with the action
creates false goal in hyperthermia application, increasing
the temperature alone. This “auto-suggestion” creates such
situation that magnetic resonance imaging (MRI) is applied
to control the temperature during the treatment, instead of
using this capable imaginarymethod to seewhat is happening
in the tumor indeed.
The non-temperature-dependent cell destruction is stud-
ied by ultrasound and widely by electric fields, which is a
hot topic in science [40, 47]. Anther line of the development
of energy absorption in depth for killing the malignant cells
was parallel: the electromagnetic treatments to cure cancer.
The first famous name was D’Arsonval. His method had
fantastic popularity at the turn of the 19th-20th centuries.
Numerous devices were developed and applied widely, but
the expected breakthrough result was missing. The first
conference in this field was organized in 1992 in Beijing.
In the beginning the galvanic electric current was used to
treat cancer. This method had delivered remarkable results;
the biological mechanisms involved in electromagnetic field
are intensively investigated and the effect of electric field
is studied on various side of its complex behavior. Some
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special treatments are established to direct electric treatment
of the tumor (mainly with DC-current), controlling the
tissue resistance, and the quality parameter is the applied
charge load. Several good surprising results reported and
conferences organized on the subject. Yet few studies discuss
the biological mechanisms involved in electromagnetic field
induced hyperthermia.
Based on microscopic effects, there not only the heating
makes the effect, but the electric field itself has a strong
synergy with this (see Figure 1), having significantly larger
cell killing in malignancy at 38∘C, than the conventional
hyperthermia has on 42∘C. The process is selective [48]. The
RF current is choosing the “easiest” path to flow, and due
to the high ionic concentration of the near-neighborhood of
malignant cells, the current will be densest at the tumor cells.
The experimental results well support this idea. In the case
of healthy cells, the load is equal for all the cells, with no
difference between the treated and control samples. When
we gain the metabolism (immortalized cells) but not yet
malignant acceleration, the effect is selectively higher but not
significant. However, when the malignancy is present, the
cellular growth is aggressive, the selection became effective,
and it kills the tumor cells without affecting the healthy ones
in the coculture.
This electric field effect well demonstrates, that the aver-
age kinetic energy (temperature) has not decisional effect.
The main action is the targeted energy-delivery, which could
be done on such low average energy as the standard healthy
body temperature.
The cell killing needs energy, and afterwards the overall
energy of the system would be decreased from a well ordered
(bounded) state (which was in the case of the living cell) to a
disordered chemical state with some broken chemical bonds.
The transition from the ordered (chemically higher energy)
state to the disordered (chemically lower state) arrangement
thewell-known gap energymust be pumped.This gap-energy
has different components. For hyperthermia the heat energy
gives the full energy consumption however, in oncothermia a
significant field effect takes part in the distortionmechanism.
This simple allows easier cell-destruction by oncothermia
(see Figure 2); similar to the well known catalytic reactions.
The large extracellular SAR makes not only thermal but
also electric inhomogenity in the tissue; the extracellular
matrix has higher current density than the other electrolytes.
The current density gradient is accompanied with the gra-
dient of the electric field, which could reorient the high-
dielectric constant proteins in the extracellular liquid. The
orientation of these protein molecules would be constrained
perpendicular on the membrane surface. By this effect the
lost adherent connections could be rebuilt in between the
malignant cells, which were indeed shown experimentally.
This effect helps to suppress the metastatic dissemination
as well as promotes the intercellular signals to activate the
natural cell-killing mechanisms.
5.3. Oncothermia Promotes the Programmed Cell-Deaths of
Tumor. Theselection and the tumor destruction of oncother-
mia became trivial hours later of the treatment. The time
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Figure 2: Oncothermia needs less thermal energy tomake the same
distortion than the classical hyperthermia does. Part of the thermal
energy is replaced by the electric field.
Figure 3: Upper panel: DAPI staining (stains the double strains of
DNA only); lower panel: TUNEL-FITC staining (enzymatic label
of the strain-break of the DNA). TUNEL is typical for necrosis
(diffuse staining) in hyperthermia and for apoptosis (staining of
nuclei locations) in oncothermia treatments.
delay indicates the long-duration processes, whichwere iden-
tified as programmed cell-death (apoptosis) [49]. Detecting
the double strains of DNA (DAPI staining; see Figure 3
upper panel) and measuring the enzymatic labeled strain-
breaks of DNA (TUNEL-FICT; see Figure 3 lower panel), the
apoptosis is highly likely in oncothermia, while at identical
temperature in classical hyperthermia the necrosis is pre-
ferred. Consequently, the main effect in oncothermia is the
apoptosis contrary to the conventional hyperthermia, which
operates mainly by necrosis. Investigating the apoptosis by
various methods (morphology, beta-catenin relocation, p53
expression, Connexin 43, Tunel, DNA-laddering, etc.), the
effects are indicating the same apoptotic process.This process
is non-toxic (no inflammatory reactions afterwards) and
promotes the immune reactions (parallel work with these)
and not makes processes against those.
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Microscopic images of cell preparations
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Figure 4: Lethality comparison with traditional hyperthermia in
vitro experiments (fixed suspension sample): HL-60 leukemia cell
line.
5.4. Oncothermia Limits the Dissemination of Malignant Cell.
Dissemination is blocked by the sticking of the cells to each
other. The adherent connections and the junctions between
the malignant cells are reestablished, the cells are connected
again, their autonomy is limited, and the possibility of the
dissemination decreases.The immune system (with presently
not clear mechanism) acts against the metastatic lesions
(abscopal, bystander effect), and the local treatment of the
primary tumor decreases the distantmetastases as well.These
effects are the most important for the survival and quality of
life.
The main threat of life by tumorous diseases is the
distortion of the organs which are essential for the life of
the organism. When the tumor grows somewhere without
endanger the important systems like the respiratory system,
central nervous system, cardiovascular system, and so forth, it
has no life-threatening efect. These tumors are local (benign
or early malignant), and effect their elimination is possible.
The real life-threatening is the malignancy, when the cells are
disseminated from the tumor-lesion by the various transport
systems (lymph and blood), or their effect become systemic
by one of the general mechanisms of the organism. The
problem of the classical hyperthermia is that sometimes it
promotes the dissemination of the malignant cells.
Oncothermia is different from this point of view as well.
It blocks the dissemination, avoiding their motility due to
the lazy connections to the tumor. Oncothermia makes it by
reestablishing the cellular connections, which is also great
success to save the life. The built up connections could force
not only the sticking together, but makes bridges between the
cells for information exchange to limit the individuality, the
competitive behavior of the malignant cells.
Comparison of hyperthermia and oncothermia com-
bined both methods with mitomycin-c (MMC) single dose
chemotherapy in vivo at tissue and cellular level using
histological examinations is shown. HT29 human colorectal
carcinoma cell line derived xenograft tumor model in nude
mouse: 2 animals for hyperthermia (42∘C) + 3mg/kg MMC
ip. (30min before the treatment) and 2 animals for oncother-
mia (42∘C)+ 3mg/kgMMC ip. (30min before the treatment).
The constrained thermodynamic transport effects destabi-
lizes the cell membrane, increases its permeability and could
make its bobbling and distortion. These are high efficacy
factors favoring oncothermia over its temperature-equivalent
hyperthermia counterpart; see Figure 4. It also produces
higher concentration of HSPs in the outer membrane and in
the extracellular matrix.The higher HSP concentration in the
vicinity of themalignant cells together with the changes of the
adherent connections between the cells induces apoptosis.
The setup made possible a fine temperature control,
which allowed to keep the heating, keeping and cooling
dynamist also identical.This makes identical heat-shock pro-
tein induction by the temperature changes.The temperature-
dependent equality was controlled by luciferase transient
transfected HEK293 cell lines. Despite the equal temperature
curves, oncothermia produces higher concentration of HSPs
in the outer membrane and in the extracellular matrix. The
higher HSP concentration, in the vicinity of the malignant
cells, is one of the factors to induce apoptosis.
Changes of adherent connections (E-cadherin and 𝛽-
catenin) are also indicators of the gain of the social sig-
nals promoting the apoptosis. Remarkable change could be
observed on beta-catenin dynamic development by time after
the treatment. on HepG2 human hepatocellular carcinoma
cell line. This considerable change after 24 hours of the
treatment is sharply different from hyperthermia on the same
temperature and supports the other observations of the non-
temperature-dependent processes. The sudden regrouping
the beta-catenin and its enrichment at the cell-nuclei could
be an indicator of apoptosis [50, 51].
Many in vitro and in vivo preclinical studies as well as
twenty years of entirely positive practice and huge number of
retrospective clinical studies are behind of oncothermia [52–
57].
Disclosure
According to European Medical Device Directive (MDD)
oncothermia is certified by TUV, Munich, by medical CE
certificate; both safety and efficacy are certified. All the
devices are manufactured according to the ISO 9001 and
ISO 13458. The devices work over 25 countries actively, and
the oncothermia is twenty years on the market. No serious
toxicity or side effects were reported. Minor adipose burns
happen in about 3% of all the large number of treatments.
As anecdotal benefit, patients report less side effects from
the conventional treatment if oncothermia is complementary
applied. They report furthermore better quality of life and
improved well-being.
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